CARM News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

Loading chart

Pay with

CA

Mkt Cap

N/A

Volume

N/A

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, HSON, TTNP on Behalf of ShareholdersLaw firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies undergoing mergers or sales transactions.GlobeNewswire Inc. · Jul 26, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVEE, CARM, HLGN on Behalf of ShareholdersLaw firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches related to merger and sale transactions involving NV5 Global, Carisma Therapeutics, and Heliogen.Benzinga · Jul 16, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: TURN, HLGN, CARM, and GNTYLaw firm Monteverde & Associates is investigating potential legal actions related to merger transactions involving four companies: 180 Degree Capital, Heliogen, Carisma Therapeutics, and Guaranty Bancshares.Benzinga · Jul 15, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BASE, CARM, ENZB on Behalf of ShareholdersLaw firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies, including Couchbase, Carisma Therapeutics, and Enzo Biochem, related to their recent sales or merger transactions.GlobeNewswire Inc. · Jul 5, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMS, BASE, CARM, ENZB on Behalf of ShareholdersLaw firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for GMS, Couchbase, Carisma Therapeutics, and Enzo Biochem related to their recent merger or sale transactions.Benzinga · Jul 1, 2025

Ocugen (OCGN) Shares Slide Following Merger Agreement: What's Going On?Ocugen's shares are trading lower after the company announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics in an all-stock deal.Benzinga · Jun 23, 2025

In-Depth Examination Of 5 Analyst Recommendations For CARISMA Therapeutics5 analysts have expressed a variety of opinions on CARISMA Therapeutics (NASDAQ:CARM) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 2 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $7.8, a high estimate of $9.00, and a low estimate of $6.00. Observing a downward trend, the current average is 13.33% lower than the prior average price target of $9.00. Deciphering Analyst Ratings: An In-Depth Analysis An in-depth analysis of recent analyst actions unveils how financial experts perceive CARISMA Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mitchell Kapoor HC Wainwright & Co. Maintains Buy $8.00 $8.00 Mitchell Kapoor HC Wainwright & Co. Maintains Buy $8.00 $8.00 Mitchell Kapoor HC Wainwright & Co. Lowers Buy $8.00 $9.00 Justin Zelin BTIG Announces Buy $6.00 - Mitchell Kapoor HC Wainwright & Co. Lowers Buy $9.00 $11.00 Key ...Full story available on Benzinga.comBenzinga · Jun 26, 2024

The Analyst Verdict: CARISMA Therapeutics In The Eyes Of 4 ExpertsIn the preceding three months, 4 analysts have released ratings for CARISMA Therapeutics (NASDAQ:CARM), presenting a wide array of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 0 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $7.75, a high estimate of $9.00, and a low estimate of $6.00. A 22.5% drop is evident in the current average compared to the previous average price target of $10.00. Investigating Analyst Ratings: An Elaborate Study A clear picture of CARISMA Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mitchell Kapoor HC Wainwright & Co. Maintains Buy $8.00 - Mitchell Kapoor HC Wainwright & Co. Lowers Buy $8.00 $9.00 Justin Zelin BTIG Announces Buy $6.00 - Mitchell Kapoor HC Wainwright & Co. Lowers Buy $9.00 $11.00 Key Insights: Action Taken: ...Full story available on Benzinga.comBenzinga · May 17, 2024

Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue EstimatesCARISMA THERAP (CARM) delivered earnings and revenue surprises of -24.32% and 12.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 9, 2024

Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseCARISMA THERAP (CARM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Zacks Investment Research · May 2, 2024

to start trading

CA

CARMCARISMA THERAPEUTICS INC

CARM

Pay with—

Available Balance0.00

Your PositionYou don't own any CARM yet.

Related Tickers

Earnings